BRIEF— InDex at the end

Swedish company InDex Pharmaceuticals have announced the departure of chief executive (CEO) Jenny Sundqvist and chief financial officer and deputy CEO Johan Giléus.

The news comes a month after the company announced that the development of its lead asset, cobitolimod, was to be discontinued after a thorough analysis of the data from the Phase III program CONCLUDE.

Wenche Rolfsen, chairman of the board, said: “Unfortunately, our Phase III study did not deliver as we had hoped for, and all current operations are being closed down. I wish both Jenny and Johan the best of luck and am certain that they will be as appreciated in their next endeavors as they have been at InDex.”